Metabolite profile of a mouse model of Charcot-Marie-Tooth type 2D neuropathy: implications for disease mechanisms and interventions

被引:6
|
作者
Bais, Preeti [1 ]
Beebe, Kirk [2 ]
Morelli, Kathryn H. [1 ,3 ]
Currie, Meagan E. [1 ]
Norberg, Sara N. [1 ]
Evsikov, Alexei V. [1 ,4 ]
Miers, Kathy E. [1 ]
Seburn, Kevin L. [1 ]
Guergueltcheva, Velina [5 ,9 ]
Kremensky, Ivo [6 ]
Jordanova, Albena [7 ,8 ]
Bult, Carol J. [1 ]
Burgess, Robert W. [1 ,3 ]
机构
[1] Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA
[2] Metabolon Inc, Durham, NC 27713 USA
[3] Univ Maine, Grad Sch Biomed Sci & Engn, Orono, ME 04469 USA
[4] Univ S Florida, Dept Mol Med, USF Hlth, Tampa, FL 33620 USA
[5] Med Univ Sofia, Dept Neurol, Sofia 1431, Bulgaria
[6] Med Univ Sofia, Univ Hosp Obstet & Gynecol, Dept Obstet & Gynecol, Natl Genet Lab, Sofia 1431, Bulgaria
[7] Univ Antwerp, VIB Dept Mol Genet, Mol Neurogen Grp, B-2610 Antwerp, Belgium
[8] Med Univ Sofia, Dept Med Chem & Biochem, Mol Med Ctr, Sofia 1431, Bulgaria
[9] Univ Hosp Sofiamed, Sofia 1797, Bulgaria
来源
Biology Open | 2016年 / 5卷 / 07期
基金
美国国家卫生研究院;
关键词
Peripheral neuropathy; Spinal cord; Sciatic nerve; Metabolomics; Mass Spectrometry; tRNA synthetase; TRANSFER-RNA SYNTHETASE; ACETYL-L-CARNITINE; ASCORBIC-ACID TREATMENT; SPINAL MUSCULAR-ATROPHY; ALPHA-LIPOIC ACID; OLD RATS; PERIPHERAL NEUROPATHY; SERINE PALMITOYLTRANSFERASE; MASS-SPECTROMETRY; METABOLOMICS DATA;
D O I
10.1242/bio.019273
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Charcot-Marie-Tooth disease encompasses a genetically heterogeneous class of heritable polyneuropathies that result in axonal degeneration in the peripheral nervous system. Charcot-Marie-Tooth type 2D neuropathy (CMT2D) is caused by dominant mutations in glycyl tRNA synthetase (GARS). Mutations in the mouse Gars gene result in a genetically and phenotypically valid animal model of CMT2D. How mutations in GARS lead to peripheral neuropathy remains controversial. To identify putative disease mechanisms, we compared metabolites isolated from the spinal cord of Gars mutant mice and their littermate controls. A profile of altered metabolites that distinguish the affected and unaffected tissue was determined. Ascorbic acid was decreased fourfold in the spinal cord of CMT2D mice, but was not altered in serum. Carnitine and its derivatives were also significantly reduced in spinal cord tissue of mutant mice, whereas glycine was elevated. Dietary supplementation with acetyl-L-carnitine improved gross motor performance of CMT2D mice, but neither acetyl-L-carnitine nor glycine supplementation altered the parameters directly assessing neuropathy. Other metabolite changes suggestive of liver and kidney dysfunction in the CMT2D mice were validated using clinical blood chemistry. These effects were not secondary to the neuromuscular phenotype, as determined by comparison with another, genetically unrelated mouse strain with similar neuromuscular dysfunction. However, these changes do not seem to be causative or consistent metabolites of CMT2D, because they were not observed in a second mouse Gars allele or in serum samples from CMT2D patients. Therefore, the metabolite 'fingerprint' we have identified for CMT2D improves our understanding of cellular biochemical changes associated with GARS mutations, but identification of efficacious treatment strategies and elucidation of the disease mechanism will require additional studies.
引用
收藏
页码:908 / 920
页数:13
相关论文
共 50 条
  • [1] Allele-specific RNA interference prevents neuropathy in Charcot-Marie-Tooth disease type 2D mouse models
    Morelli, Kathryn H.
    Griffin, Laurie B.
    Pyne, Nettie K.
    Wallace, Lindsay M.
    Fowler, Allison M.
    Oprescu, Stephanie N.
    Takase, Ryuichi
    Wei, Na
    Meyer-Schuman, Rebecca
    Mellacheruvu, Dattatreya
    Kitzman, Jacob O.
    Kocen, Samuel G.
    Hines, Timothy J.
    Spaulding, Emily L.
    Lupski, James R.
    Nesvizhskii, Alexey
    Mancias, Pedro
    Butler, Ian J.
    Yang, Xiang-Lei
    Hou, Ya-Ming
    Antonellis, Anthony
    Harper, Scott Q.
    Burgess, Robert W.
    JOURNAL OF CLINICAL INVESTIGATION, 2019, 129 (12): : 5568 - 5583
  • [2] Reversal of neuropathy phenotypes in conditional mouse model of Charcot-Marie-Tooth disease type 2E
    Dequen, Florence
    Filali, Mohammed
    Lariviere, Roxanne C.
    Perrot, Rodolphe
    Hisanaga, Shin-Ichi
    Julien, Jean-Pierre
    HUMAN MOLECULAR GENETICS, 2010, 19 (13) : 2616 - 2629
  • [3] Charcot-Marie-Tooth disease type 2
    Vance, JM
    CHARCOT-MARIE-TOOTH DISORDERS, 1999, 883 : 42 - 46
  • [4] Type 2 Charcot-Marie-Tooth disease
    Combarros-Pascual, O
    REVISTA DE NEUROLOGIA, 2000, 30 (01) : 79 - 81
  • [5] Optic Neuropathy in Charcot-Marie-Tooth Disease
    Hamedani, Ali G.
    Wilson, James A.
    Avery, Robert A.
    Scherer, Steven S.
    JOURNAL OF NEURO-OPHTHALMOLOGY, 2021, 41 (02) : 233 - 238
  • [6] Genetic heterogeneity in Charcot-Marie-Tooth neuropathy type 2
    Yoshioka, R
    Dyck, PJ
    Chance, PF
    NEUROLOGY, 1996, 46 (02) : 569 - 571
  • [7] A PERSONALIZED GENE THERAPY APPROACH FOR CHARCOT-MARIE-TOOTH DISEASE TYPE 2D
    Morelli, K. H.
    Domire, J. S.
    Pyne, N.
    Fowler, A.
    Harper, S.
    Burgess, R. W.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2016, 21 (03) : 281 - 282
  • [8] TRANSLATIONAL PROFILING OF MOTOR NEURONS IN TWO MOUSE MODELS OF CHARCOT-MARIE-TOOTH DISEASE TYPE 2D
    Spaulding, E.
    Burgess, R.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2016, 21 (03) : 302 - 303
  • [9] Neuropathy progression in Charcot-Marie-Tooth disease type 1A
    Shy, M. E.
    Chen, L.
    Swan, E. R.
    Taube, R.
    Krajewski, K. M.
    Herrmann, D.
    Lewis, R. A.
    McDermott, M. P.
    NEUROLOGY, 2008, 70 (05) : 378 - 383
  • [10] Phenotype of Charcot-Marie-Tooth disease Type 2
    Bienfait, H. M. E.
    Baas, F.
    Koelman, J. H. T. M.
    de Haan, R. J.
    van Engelen, B. G. M.
    Gabreels-Festen, A. A. W. M.
    de Visser, B. W. Ongerboer
    Meggouh, F.
    Weterman, M. A. J.
    De Jonghe, P.
    Timmerman, V.
    de Visser, M.
    NEUROLOGY, 2007, 68 (20) : 1658 - 1667